Figure 1.

A Sativex®-like combination of phytocannabinoids, Δ⁹-THC-BDS or CBD-BDS treatments alone, significantly improved motor deficits in the chronic phase of TMEV infection. SJL/J mice were intracranially inoculated with TMEV or the vehicle alone and after 70 days, once the symptomatology was established, the mice were treated i.p. for 10 consecutive days with a Sativex-like combination of phytocannabinoids (10 mg·kg⁻¹), CBD-BDS (5 mg·kg⁻¹), Δ⁹-THC-BDS (5 mg·kg⁻¹) or the vehicle alone. On the last day of treatment, motor function was evaluated by measuring horizontal (HACTV) and vertical activity (VACTV) in the activity cage test (A) which revealed a significant attenuation of motor deficits in the TMEV-IDD model following Sativex administration. In a comparative analysis, Sativex and CBD-BDS alone were the most effective treatments as they abolished the decreased motor activity and restored the normal levels of HACTV (B). Activity parameters were recorded for 10 min and the results are represented as the mean ± SEM of nine mice per group: ***P ≤ 0.001 versus Sham; ##P ≤ 0.01; ###P ≤ 0.001 versus TMEV-VEH animals; ⋆⋆⋆P ≤ 0.001 versus TMEV-Sativex; ^*P ≤ 0.05 TMEV-CBD-BDS versus TMEV-THC-BDS (non parametric Kruskal–Wallis test). NS, not significant.